SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
Under the Securities Exchange Act of 1934
Amendment No.8
--------
DENNY'S CORPORATION
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
24869P104
(CUSIP Number)
Mellon HBV Alternative Strategies LLC
200 Park Avenue, Suite 3300
New York, NY 10166-3399
(212) 808-3950
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
February 14, 2005
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box.
Note: Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page. The information required on
the remainder of this cover page shall not be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or
otherwise subject to the liabilities of that section of the Act but shall be
subject to all other provisions of the Act (however, see the Notes).
Page 1 of 5
CUSIP No.: 24869P104 Page 2 0f 5
1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Mellon HBV Alternative Strategies LLC
I.R.S. No.: 13-4050836
---------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) (b)
---------------------------------------------------------------------------
3 SEC USE ONLY
---------------------------------------------------------------------------
4 SOURCE OF FUNDS*
00
---------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e)
---------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
---------------------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING
PERSON WITH
---------------------------------------------------------------------------
7 SOLE VOTING POWER
8,719,773
---------------------------------------------------------------------------
8 SHARED VOTING POWER
0
---------------------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
8,719,773
---------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
---------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON
8,719,773
---------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
---------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.7%
---------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IA
---------------------------------------------------------------------------
Page 3 0f 5
Introduction:
This Amendment No. 8 to the Schedule 13D is being filed by the Reporting
Person to reflect sale transactions of the Company's Common Stock previously
disclosed on a Forms 4 recently filed by the Reporting Person.
Item 1. Security and Issuer
Security: Common Stock, $0.01 par value per share ("Common Stock").
Issuer's Name and Address:
Denny's Corporation (the "Company"), 203 E. Main Street, Spartanburg,
SC 29319-9966.
Item 2. Identity and Background
(a) Mellon HBV Alternative Strategies LLC (the "Reporting Person")
which acts as investment advisor and authorized agent for each of the
funds named on Exhibit A hereto. Each such fund sold for its
respective account the number of shares of the Common Stock set forth
opposite its name on Exhibit A.
(b) The Reporting Person is a Delaware limited liability company with
its principal executive offices located at 200 Park Avenue, Suite
3300, New York, NY 10166-3399.
(c) The Reporting Person serves as investment advisor of Mellon HBV
Master Rediscovered Opportunities Fund L.P., Mellon HBV Master
Multi-Strategy Fund L.P., Axis RDO Ltd., Mellon HBV Capital Partners
L.P., Mellon HBV Distressed Recovery Master Fund Ltd., Mellon HBV
Leveraged Multi-Strategy Fund L.P., Mellon HBV Master U.S. Event
Driven Funds L.P., Lyxor/Mellon HBV Rediscovered Opportunity Fund Ltd.
and HFR DS Performance Master Trust (collectively, the "Clients"). The
Reporting Person has sole voting and dispository power over the shares
of Common Stock held by each such fund.
(d)-(e) During the last five years neither the Reporting Person, nor,
to the best of its knowledge, any of its directors, executive
officers, controlling persons or members, has been (i) convicted of
any criminal proceeding (excluding traffic violations or similar
misdemeanors) or (ii) a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and as a result of such
proceeding was or is subject to a judgment, decree or final order
enjoining future violations of, or prohibiting or mandating activities
subject to federal or state securities laws or finding any violation
with respect to such laws.
Item 4. Purpose of Transaction
In view of the fact that the Reporting Person's beneficial ownership
in the Common Stock of the Issuer is now significantly less than 20%
and that the Reporting Person has no intent to directly or indirectly
change or influence the control of the Issuer, the Reporting Person
will henceforth report its passive investment in the Issuer's Common
Stock on Schedule 13G and intends to file its initial Schedule 13G
with respect to the Issuer's Common Stock immediately following the
receipt by the Commission of this Amendment No. 8 to Schedule 13D.
Item 5. Interest in Securities of the Issuer
(a) As of February 14, 2005, the Reporting Person beneficially owned
in the aggregate 8,719,773 shares of the Company's Common Stock (the
"Shares"), representing approximately 9.7% of the outstanding Common
Stock (based on 89,987,134 shares issued and outstanding as of January
5, 2005, as reported in the Company's Form 8A/A filed on January 12,
2005).
(b) The Reporting Person has the sole power to vote or to direct the
vote and the sole power to dispose and to direct the disposition of
the Shares.
(c) Information relating to the transaction effected by the Reporting
Person with respect to the Common Stock appears on Exhibit A attached
hereto.
(d) Not applicable.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with
Respect to Securities of the Issuer
None.
Item 7. Material to be Filed as Exhibits
None.
Page 4 of 5
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: February 16 , 2005
MELLON HBV ALTERNATIVE STRATEGIES LLC.
By: /s/ WILLIAM F. HARLEY III
--------------------------------------------
William F. Harley III
President and Chief Executive Officer
Page 5 of 5
Exhibit A
Information with respect to sales of the Common Stock of the Company
effected by the Reporting Person since the Reporting Person's last filing on
Schedule 13D relating to the Company.
-------------------------------- -------------------- ----------- -----------
NAME OF FUND DATE Sale Price SHARES
-------------------- ----------- -----------
Mellon HBV Master Rediscovered 2/14/2005 $4.95 47,589
Opportunities Fund, L.P.
-------------------- ----------- -----------
2/14/2005 $4.95 7,500
-------------------------------- -------------------- ----------- -----------
Mellon HBV Master 2/14/2005 $4.95 24,512
Multi-Strategy Fund L.P.
-------------------------------- -------------------- ----------- -----------
Axis-RDO Limited 2/14/2005 $4.95 6,524
-------------------------------- -------------------- ----------- -----------
HFR DS Performance Master Trust 2/14/2005 $4.95 7,374
-------------------------------- -------------------- ----------- -----------
Distressed Recovery Master 2/14/2005 $4.95 3,775
Fund Ltd.
-------------------------------- -------------------- ----------- -----------
Mellon HBV Master U.S. Event 2/14/2005 $4.95 1,333
Driven Funds L.P.
-------------------------------- -------------------- ----------- -----------
Lyxor/Mellon HBV Rediscovered 2/14/2005 $4.95 8,893
Opportunities Fund Ltd.
-------------------------------- -------------------- ----------- -----------